Cravath Steers J&J Buy Of Skadden-Led Ambrx In $2B Deal
By Jade Martinez-Pogue · January 8, 2024, 1:24 PM EST
Pharmaceutical industry giant Johnson & Johnson, advised by Cravath Swaine & Moore LLP, is buying San Diego, California-based clinical-stage biopharmaceutical company Ambrx Biopharma Inc., advised by Skadden Arps Slate Meagher &...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login